The new cassettes are constructed with high-performance materials that reduce extractables to deliver high-purity biological solutions
Biopharmaceutical manufacturers require efficient, high-throughput ultrafiltration technologies to handle higher protein concentrations.
To address this need, Pall introduces the new Omega T-series membrane cassettes to offer enhanced processing efficiencies and greater product recovery.
These cassettes assure effective mass transfer of proteins, which is critical for biotech manufacturers given the significant cost of even minimal volumes of purified protein solutions used in downstream drug production.
Pall also introduces single-use Minimate II encapsulated membrane cassettes, the latest addition to the company's line of single-use technologies.
